July 20, 2017: Did you hear the latest news from across the Big Ten Cancer Research Consortium? While it may seem impossible to keep pace with the member institutions in their fight against cancer, you do not have to miss the action. From historic moments, to monumental studies, to game-changing discoveries, you can celebrate the latest wins every time you tune in for another monthly edition of Across the Consortium! Read More
July 16, 2017: The Indiana University Melvin and Bren Simon Cancer Center hosted Doug Lowy, the acting director of the National Cancer Institute, for a full-day visit on June 28. (Photo: Drs. Schneider (left) and Milan Radovich (middle) explain their work on the next generation of personalized medicine with Dr. Doug Lowy, acting director of the National Cancer Institute. Dr. Lowy visited the IU Simon Cancer Center on June 28. Photo credit: IU Simon Cancer Center) In a series of small-group discussions in the morning, he met with cancer center members (members' names appear in bold) and others to learn about: Pediatric genomics with D. Wade... Read More
June 20, 2017: Summer is officially here and so is the hottest news in cancer research - at your fingertips in this month's edition of Across the Consortium. Get up to date on the latest discoveries, game-changing breakthroughs, and big-time funding achievements. Don't miss the inspirational moments that go down in history, from the dedication of the "Search" Tower to a discussion with family of Henrietta Lacks - source of the HeLa cell line. All this and more as we take you Across the Consortium! Read More
June 7, 2017 The Big Ten Cancer Research Consortium recently welcomed Diane M. Hershock, MD, PhD, of Penn State Cancer Institute, as a member of its Steering Committee. The committee consists of one representative from each member institution and is responsible to decide matters of policy for the consortium. Hershock is co-director for experimental therapeutics and medical director in the Clinical Trials Office at Penn State Cancer Institute. She earned her Bachelor of Science in biology from Saint Joseph's University in Philadelphia and spent four years doing biochemistry in the thrombosis and hemostasis department at Temple University Medical School. “We were trying to develop an antibody to the GPIIb/IIIa receptor as... Read More
June 2, 2017: Investigator Spotlight Dr. Ryan Alan Wilcox Ryan Alan Wilcox, M.D., Ph.D., assistant professor of hematology, University of Michigan Comprehensive Cancer Center Member of the Big Ten Cancer Research Consortium Lymphoid Malignancies Clinical Trial Working Group Interests: T-cell non-Hodgkin’s lymphomas Medical School or Training Mayo Medical School, 2004 Residency Mayo Clinic, Internal Medicine, MN, 2007 Fellowship Hematology/Oncology, Mayo Clinic, 2011 Board Certification Internal Medicine Medical Oncology Hematology Read More
May 31, 2017: Dustin Deming, MD, is a gastrointestinal oncologist at the University of Wisconsin Carbone Cancer Center (UWCCC) and the William S. Middleton Veterans Hospital with subspecialties in the treatment of colon, rectal, and anal cancers. Deming’s commitment to the field is no coincidence; his first-hand exposure to clinical oncology opened his eyes to opportunities to apply his lab science strengths. “I had thought I wanted to be a pathologist and focus mostly on basic science research, because I had kind of been a lab rat for the beginning portion of my career. Once I actually got into the clinic, I realized how exciting it was to be involved in many aspects of colorectal research: things as... Read More
May 26, 2017: Lung cancer researchers at the Indiana University Melvin and Bren Simon Cancer Center have opened a clinical trial testing the effects of immunotherapy in combination with next-line chemotherapy in patients who experienced some benefit from immunotherapy before their disease worsened. The single-arm phase II study, known as BTCRC-LUN15-029, will enroll about 35 subjects with advanced non-small cell lung cancer who were treated with a PD-1 (programmed death-1) or PD-L1 (programmed death-ligand 1) inhibitor and experienced either stable disease or a partial or complete response before their disease worsened. The study is now open to accrual at the Indiana University Melvin... Read More
May 26, 2017: A Big Ten Cancer Research Consortium study is evaluating the safety and efficacy of durvalumab (MEDI4736) following multi-modality therapy in esophageal cancer. The phase II study, known as BTCRC-ESO14-012, is currently open for accrual at the Indiana University Melvin and Bren Simon Cancer Center, the University of Illinois Cancer Center, the Holden Comprehensive Cancer Center at the University of Iowa, Michigan State University Breslin Cancer Center, and the University of Michigan Comprehensive Cancer Center. Read More
May 22, 2017: Across the Consortium is your chance to catch the latest news in Big Ten oncology as it happens each month. We handpick the breaking stories that keep you informed and inspired. This month's edition highlights major breakthroughs in diagnostics, therapeutics, and discovery. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube